

ASX / MEDIA ANNOUNCEMENT

6 May 2020

Respiri completes oversubscribed Share Purchase Plan offer

Respiri Limited (ASX:RSH) (“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management, is pleased to announce the completion of its Share Purchase Plan offer (SPP) previously announced to the ASX on 9 April 2020. The Company lodged a Prospectus in relation to the SPP offer on 9 April 2020 followed by a Supplementary Prospectus on 5 May 2020.

The SPP offer provided eligible shareholders the opportunity to subscribe for up to 57,090,909 of new shares ordinary shares in the Company at an issue price of \$0.055, subject to scale back at the Company’s discretion. The maximum to be raised under the SPP offer was \$3,140,000.

The SPP offer was heavily supported by eligible shareholders and Respiri received significant oversubscriptions based on the original offer size of \$1,000,000. Consequently, in accordance with the terms and conditions of the SPP offer, the Company will scale back the allotment of new shares under the SPP offer to \$3,140,000.

The Company would like to express its deep appreciation to all eligible shareholders who participated in the SPP offer and thanks shareholders for this vote of confidence and their continued support. The Company is now well capitalised to implement its plans through to launch later in the year, having raised a total of \$5.1 million by way of a share placement and SPP.

The new shares under the SPP offer will be issued to eligible applicants on Friday, 8 May 2020 in accordance with the timetable set out in the Prospectus dated 9 April 2020. Holdings statements and CHESS notices will be dispatched, and refunds of subscription monies due to the scale back will be made on or around Monday, 11 May 2020.

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
 CEO & Managing Director
 Respiri Limited
 P: +61 408 462 873
 E: marjan@respiri.co

Mr Nicholas Smedley
 Executive Chairman
 Respiri Limited
 P: +61 447 074 160
 E: nicholas@respiri.co

This ASX announcement dated 6 May 2020 has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user’s personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit www.respiri.co

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respiri only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.